X
<

Novo Nordisk and How It's Positioned after the 1st Half of 2017

PART:
1 2 3 4 5 6 7
Part 7
Novo Nordisk and How It's Positioned after the 1st Half of 2017 PART 7 OF 7

A Look at Novo Nordisk’s Hemophilia Franchise after 2Q17

Hemophilia franchise revenue trends

In the first half of 2017, Novo Nordisk’s hemophilia franchise reported revenues of DKK (Danish kroner) 5.3 billion, which reflected a ~1.0% fall on a YoY (year-over-year) basis. In that period, the fall in sales for hemophilia products was primarily driven by lower sales of NovoSeven in Latin America and Japan and Korea. However, the roll-out of NovoEight in Europe and increasing sales of NovoSeven in Europe partially offset the fall in sales in other regions.

In 2Q17, Novo Nordisk’s (NVO) hemophilia franchise generated revenues of DKK 2.7 billion, which reflected an 8.0% rise on a YoY basis and a 6.0% rise on a QoQ (quarter-over-quarter) basis.

In 2Q17, NovoSeven generated revenues of DKK 2.4 billion, which is a 2.0% rise on a QoQ basis. In 2Q17, Novo Nordisk’s NovoEight generated revenues of DKK 347.0 million compared to DKK 229.0 million in 1Q17.

A Look at Novo Nordisk’s Hemophilia Franchise after 2Q17

Interested in ADRD? Don't miss the next report.

Receive e-mail alerts for new research on ADRD

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

The above chart represents the revenue curve of Novo Nordisk’s hemophilia franchise.

NovoSeven and NovoEight

NovoSeven is a recombinant coagulation factor VIIa used for the management of bleeding episodes and perioperative management in individuals with hemophilia A or B with inhibitors, a congenital Factor VII (or FVII) deficiency. NovoSeven is also indicated for the treatment of Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets. NovoSeven has also been indicated for the management of bleeding episodes and perioperative management in adult individuals with acquired hemophilia.

NovoEight is a recombinant antihemophilic factor used in individuals with hemophilia A for control and prevention of bleeding, perioperative management, and reduction of the frequency of bleeding episodes.

Novo Nordisk’s peers in the hemophilia drug market include Bioverativ (BIVV), Bayer (BAYZF), Shire (SHPG), and others. Biogen (BIIB) spun off its anti-hemophilia drug business, and a new company Bioverativ was formed.

The growth in Novo Nordisk’s hemophilia franchise could boost the share prices of the BLDRS Developed Markets 100 ADR ETF (ADRD). Novo Nordisk makes up ~2.2% of ADRD’s total portfolio holdings.

X

Please select a profession that best describes you: